Dizal (jiangsu) Pharmaceutical Co. Ltd. Class ASSE: 688192

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review

· Issued by Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-the-acceptance-of-the-new-drug-application-for-sunvozertinib-as-first-line-monotherapy-for-egfr-exon20ins-non-small-cell-lung-cancer-by-the-national-medical-products-administration-and-its-inclusion-in-priority-review

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis